Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
ocrevus | Biologic Licensing Application | 2024-11-19 |
ocrevus zunovo | Biologic Licensing Application | 2024-11-19 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple sclerosis | EFO_0003885 | D009103 | G35 |
extravasation of diagnostic and therapeutic materials | — | D005119 | — |
Code | Description |
---|---|
J2350 | Injection, ocrelizumab, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 4 | 8 | 12 | 25 |
Sclerosis | D012598 | — | — | — | 1 | 3 | 7 | 11 | 22 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | 2 | 4 | 2 | 9 |
Neuroinflammatory diseases | D000090862 | — | — | — | — | — | 1 | — | 1 |
Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 2 | 4 | — | — | 6 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 2 | 4 | — | — | 6 |
Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | 1 | — | 4 | 5 |
Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | 2 | — | — | 2 |
Lupus nephritis | D008181 | EFO_0005761 | — | — | — | 1 | — | — | 1 |
Nephritis | D009393 | — | N05 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | — | — | — | 1 |
Psychotic disorders | D011618 | — | F20.81 | 1 | 1 | — | — | — | 1 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | 1 | — | — | — | 1 |
Autoimmune diseases of the nervous system | D020274 | — | — | — | 1 | — | — | — | 1 |
Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | 1 | — | — | — | 1 |
Encephalitis | D004660 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Immune system diseases | D007154 | — | D89.9 | — | — | — | — | 1 | 1 |
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | — | 1 | 1 |
Nervous system diseases | D009422 | — | G00-G99 | — | — | — | — | 1 | 1 |
Demyelinating diseases | D003711 | — | — | — | — | — | — | 1 | 1 |
Pathologic processes | D010335 | — | — | — | — | — | — | 1 | 1 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Drug common name | Ocrelizumab |
INN | ocrelizumab |
Description | Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.
... More |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108041 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11988 |
UNII ID | A10SJL62JY (ChemIDplus, GSRS) |